Peak Sales Potential of Merck's (MRK) Keytruda is Underappreciated - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
| Merck & Co. (NYSE: MRK) | Delayed: 145.60 +3.22 (2.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $142.38 | 52 Week High | $65.46 | |||
| Open | $141.37 | 52 Week Low | $47.97 | |||
| Day High | $146.68 | P/E | 99.05 | |||
| Day Low | $141.36 | EPS | $1.47 | |||
| Volume | 7,990,609 | |||||
